Analysis and Quantitation of the β-Amyloid Precursor Protein in the Cerebrospinal Fluid of Alzheimer's Disease Patients with a Monoclonal Antibody-Based Immunoassay |
| |
Authors: | Thomas Henriksson,Robin M. Barbour,Sonia Braa,Pamela Ward,Lawrence C. Fritz,Kelly Johnson-Wood,Hyung D. Chung,William Burke,Kari J. Reinikainen&dagger ,Paavo Riekkinen&dagger ,Dale B. Schenk |
| |
Affiliation: | Athena Neurosciences, Inc., South San Francisco, California 94080. |
| |
Abstract: | One of the major clinical findings in Alzheimer's disease (AD) is the formation of deposits of beta-amyloid protein in amyloid plaques, derived from the beta-amyloid precursor protein (beta-APP). To determine the possible use of beta-APP as a diagnostic marker for AD in CSF, a monoclonal antibody-based immunoassay specific for this protein was developed. The assay does not differentiate between beta-APP695 and beta-APP751 forms but does preferentially recognize beta-APP751 complexed with a protease. Of the two sets of CSF samples tested, one set, obtained from living patients, gave a slightly lower level of beta-APP in AD and Parkinson's disease patients relative to controls, whereas the other set, composed of postmortem samples, showed no significant differences between the AD and control groups. |
| |
Keywords: | β-Amyloid precursor protein Monoclonal antibody CSF Alzheimer's disease |
|
|